Marco Bertini, R&D and Medical Affairs ManagerOriginality has defined Laboratori Baldacci S.p.A., an Italian pharmaceutical company, for more than a century. Founded in Pisa in 1904 by Dr Valentino Baldacci, it was built on one conviction. Only original, patented compounds validated through its own research earn a place in its portfolio.
That principle has endured across generations of Baldacci family leadership, shaped by medical professionals. Pharmacologists, physicians and academic figures have guided its direction, reinforcing a model in which medical thinking drives development.
Baldacci operates as a fully integrated organisation, combining internal research, patent-led development, controlled manufacturing and physician-focused scientific engagement. R&D is not a supporting function. It is the core of Baldacci’s identity, shaping how it identifies clinical gaps and strengthens the value of each therapy over time. Its portfolio of more than 10 product patents in more than 20 countries reflects its way of thinking. That structure is what moves differentiated compounds into clinical practice, particularly in gynaecology and neuro-psychiatry.
“We don’t put new compounds on the market every year,” explains Marco Bertini, R&D and Medical Affairs Manager. “We try to reinforce the added value of the ones we have.”
A Portfolio Built on Clinical Evidence
How does integrated pharmaceutical research support development of clinically differentiated medical therapies today?
Baldacci has worked with gynaecologists for over 50 years and with neuropsychiatrists for many years, developing original therapies in both areas. Research, chemical, analytical and manufacturing teams work in parallel from the start of each project, resolving formulation, pharmacokinetics and batch standardisation together rather than sequentially.
-
We don’t put new compounds on the market every year. We try to reinforce the added value of the ones we have.
Its treatment for chronic venous insufficiency is the only drug worldwide shown to improve the quality of life in affected patients. A Cochrane systematic review, regarded as among the most impactful forms of clinical evidence, confirms that distinction. In gynaecology, a topical symbiotic therapy for bacterial vaginosis, backed by clinical studies enrolling more than 4,000 patients, offers a targeted complementary treatment to antibiotics. Always for Gynecologists we were the first Company in Italy marketed a compound ables to significantly reduce the incidence of congenital malformations in newborn according to The Lancet recommendations. In iron deficiency and anaemia, a patented oral formulation achieves higher bioavailability than conventional iron salts and shows efficacy in conditions where only parenteral iron had previously worked. Its therapy for Raynaud’s phenomenon has demonstrated safety and efficacy in pre-clinical and clinical settings. In neuropsychiatry, research into benzodiazepine withdrawal, studied for its links to Alzheimer’s disease, addresses a social problem concentrated among older patients.
Why is post-registration clinical research important for understanding long-term therapeutic treatment outcomes?
What Bertini describes as clinical product fostering defines how Baldacci builds on each therapy after registration. Real-world patients carry comorbidities that trials exclude. Post-registration study is where the drug’s full potential is understood.
Built on Trust with Medical Doctors
In what way does scientific engagement strengthen relationships between pharmaceutical companies and physicians?
Baldacci’s commercial model operates entirely through medical doctors. Nearly 100 scientifically trained representatives work across Italy, engaging specialists through clinical evidence and direct scientific exchange. When a doctor wants to understand something scientific, they turn to Baldacci’s field team. That trust, built over more than a century, is why doctors prescribe its therapies.
A recent European partnership illustrates how the model scales. Baldacci was entrusted with the Italian market for a traditional herbal medicine, registered under EMA monographs for anxiety and sleep disorders. Direct scientific engagement with psychiatrists, neuropsychiatrists and children’s neuropsychiatrists, combined with strong field execution, helped the therapy become one of the most-selling compounds in its indication in Italy within a short period. The publications and clinical work produced in Italy subsequently shaped the drug’s broader R&D direction. Baldacci is now recognised as that company’s premium partner across Europe.
Advancing the Next Phase
Recognised as the Top Gynaecology and Neuro-Psychiatry Medicine Development Company in Europe for 2026, Baldacci is developing new patented compounds in neuropsychiatry to improve patient compliance, while expanding into paediatrics and gastroenterology. Its organisation is agile and medically led. Where large pharmaceutical companies require many internal steps before a decision moves forward, Baldacci decides and acts immediately. That speed, grounded in more than 120 years of clinical credibility, defines what it brings to any partnership.
Laboratori Baldacci S.p.A. continues to work with and for medical doctors, building therapies proven in research and in practice.
Advancing Precision in Gynaecology and Neuro-Psychiatry Therapeutics
Therapeutic development in gynaecology and neuro-psychiatry presents a distinct challenge for decision-makers. Clinical variability remains high, particularly in neuro-psychiatric conditions where prescribing often relies on iterative adjustment rather than predictable response. In gynaecology, conventional treatment pathways still rely heavily on standardised interventions that may not account for individual microbiological or metabolic differences. Executives responsible for sourcing development partners must therefore look beyond scale or speed and focus on scientific depth, clinical validation discipline and ability to translate research into sustained physician confidence.
A defining tension in this space lies in how innovation is generated and validated. Many development models prioritise rapid product turnover, introducing frequent variations without fully reinforcing clinical understanding. This approach creates fragmentation in physician trust and limits long-term adoption. A more effective model centres on the original compound development supported by continuous post-registration studies, where real-world patient conditions refine therapeutic insights beyond controlled trial environments. The ability to extend clinical investigation after regulatory approval signals a commitment to understanding treatment performance in complex, comorbid conditions rather than relying solely on initial efficacy data, thereby ensuring greater clinical relevance.
Equally important is the relationship between therapeutic developers and the prescribing community. Products gain traction not only through data but through the credibility of scientific exchange that supports them. When engagement is structured around informed dialogue with clinicians, rather than broad marketing channels, it fosters a level of trust that directly influences prescribing behaviour. This dynamic becomes critical in specialities such as neuro-psychiatry and gynaecology, where physicians require confidence in both mechanism and outcome before adopting new approaches. Strong field representation grounded in scientific knowledge, rather than promotional messaging, reinforces this trust and ensures that therapeutic differentiation is clearly understood in practice and applied consistently.
Another point of differentiation emerges in how companies approach their own treatment pathways. Conventional pharmacological strategies often follow established biochemical routes, yet emerging evidence highlights the value of alternative mechanisms, such as modulation beyond monoaminergic systems or microbiota-focused interventions in gynaecological care. Organisations that invest in these differentiated approaches, supported by rigorous clinical publications and regulatory-grade evidence, are better positioned to address unmet needs and improve the predictability of patient outcomes. Depth of publication in high-impact journals and adherence to international clinical standards further signal the reliability of such innovation and sustained scientific credibility.
Laboratori Baldacci S.p.A exemplifies this model through a tightly integrated structure that connects research, clinical validation, manufacturing and commercialisation within a single framework. Its long-standing focus on developing proprietary, patented compounds rather than replicating existing treatments aligns directly with the need for differentiated therapeutic pathways. The company reinforces its products through sustained clinical investigation, including post-registration clinical work, published studies and large patient cohorts in selected programmes, which strengthens physician confidence over time. Its emphasis on direct engagement with medical professionals, supported by scientifically trained representatives, ensures that knowledge transfer remains central to adoption. In gynaecology, its work with topical symbiotic approaches to vaginal health demonstrates a shift away from reliance on conventional antibiotics, while in neuro-psychiatry, its portfolio includes compounds such as metadoxine and other differentiated approaches developed or advanced through its research and partnership model. This combination of original research, ongoing clinical reinforcement and physician-centred engagement positions it as a credible partner for organisations seeking consistent, evidence-based therapeutic development.
...Read more
Gynecology and Neurology Medicine Development Info
Q1
What Is Gynecology and Neuro-Psychiatry Medicine Development in Europe?
Gynecology and Neuro-Psychiatry Medicine Development in Europe encompasses the research, clinical validation and continued development of therapies addressing needs across women’s health and neuropsychiatric care. The work extends beyond discovering compounds to include formulation, pharmacokinetics, manufacturing consistency and evidence generation. In both areas, sustained clinical investigation can help establish how therapies perform in real-world settings and across patients with complex conditions.
Q2
How Does Laboratori Baldacci S.p.A. Approach This Area?
Laboratori Baldacci S.p.A. follows an integrated model in which research, chemical and analytical work, manufacturing and medical engagement operate together from the beginning of a development program. The company has worked with gynecologists for more than 50 years and has also developed therapies in neuropsychiatry. Its portfolio includes more than 10 product patents across more than 20 countries, reflecting its focus on proprietary compounds and continued therapeutic development. This structure supports its work in Gynecology and Neuro-Psychiatry Medicine Development in Europe.
Q3
What Capabilities Matter in Gynecology and Neuro-Psychiatry Medicine Development?
Effective Gynecology and Neuro-Psychiatry Medicine Development in Europe requires more than initial drug discovery. Development teams need to consider formulation, pharmacokinetics, analytical controls, batch standardization and clinical evidence as connected parts of the process. Post-registration research is also important because patients treated in routine practice may have comorbidities and other characteristics not represented in controlled trials. These studies can reveal additional information about therapeutic performance over time.
Q4
Why Is Post-Registration Research Important?
Post-registration research allows Gynecology and Neuro-Psychiatry Medicine Development in Europe to extend beyond the evidence generated before approval. Real-world studies can examine treatment performance among broader patient populations and provide insight into long-term use. Laboratori Baldacci S.p.A. describes this approach as “clinical product fostering,” using continued investigation to understand and reinforce the value of existing therapies rather than relying solely on new product introductions.
Q5
How Can Physician Engagement Strengthen Therapeutic Development?
Scientific exchange with physicians is an important part of Gynecology and Neuro-Psychiatry Medicine Development in Europe because clinicians need reliable evidence to understand how differentiated therapies perform in practice. A scientifically trained field organization can support this exchange through direct discussions around clinical evidence. Laboratori Baldacci S.p.A. has nearly 100 scientifically trained representatives working across Italy and engages specialists through clinical information and scientific dialogue rather than relying solely on conventional commercial communication.
Q6
What Developments Are Shaping This Therapeutic Area?
Gynecology and Neuro-Psychiatry Medicine Development in Europe is increasingly focused on differentiated treatment approaches supported by continued clinical evidence. In gynecology, this includes targeted approaches such as topical symbiotic therapy for bacterial vaginosis. In neuropsychiatry, development is addressing areas such as benzodiazepine withdrawal and patient compliance. Laboratori Baldacci S.p.A. is also developing new patented neuropsychiatric compounds while expanding its research focus into pediatrics and gastroenterology.
